Lipopolysaccharide-targeting treatments for multidrug-resistant <i>Pseudomonas aeruginosa</i>

Pyocins, bacteriocins produced by <i>P.</i> <i>aeruginosa</i>, are an attractive potential treatment for MDR infections. Their high species-specificity, effective bactericidal activity, and relative stability and safety give them a promising treatment profile. It is likely that pyocin treatments could enter clinical testing, offering another lifeline for the future of combating <i>P. aeruginosa</i>.